Blood and Blood Components Market By Product Type (Whole Blood, Red Blood Cells, Platelets, Plasma, Cryoprecipitate), By End-User (Hospitals, Blood Banks, Diagnostic Centers, Research Institutes), By Application (Transfusion, Hematology, Oncology, Trauma Care, Surgery), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Blood and Blood Components Market was valued at USD 31.2 Billion in 2024-e and will surpass USD 54.2 Billion by 2030; growing at a CAGR of 9.7% during 2025-2030.

The global blood and blood components market has experienced steady growth, driven by the increasing demand for blood transfusions, advancements in blood processing technologies, and an aging population requiring medical procedures. Blood components such as red blood cells, plasma, platelets, and cryoprecipitate are essential in a range of medical treatments, including trauma care, surgeries, and the management of chronic conditions such as hemophilia. These critical elements are sourced from blood donation drives and processed to ensure safety, efficacy, and optimal therapeutic outcomes. Market players are continually innovating to improve blood preservation, collection, and distribution techniques while addressing growing demand across various regions.

The market’s growth is also spurred by a robust healthcare infrastructure, the rise in blood-related diseases, and government initiatives to promote voluntary blood donation. Blood banks, hospitals, and diagnostic centers are primary consumers of these products, thus contributing to the expansion of the market. Furthermore, geographic factors significantly impact market trends, with varying demand and regulatory environments across regions.

Product Type Segment Is Largest Owing To Rising Demand for Plasma

The plasma segment stands as the largest subsegment within the blood and blood components market, largely due to its wide range of therapeutic applications. Plasma is essential for the production of clotting factor concentrates used in treating hemophilia and other bleeding disorders. Additionally, plasma-derived therapies are increasingly used for treating immune deficiencies, respiratory diseases, and liver disorders. The growing demand for these treatments has led to an expansion in plasma collection and processing capabilities worldwide.

Plasma's versatility in medical applications, coupled with the high demand for immunoglobulin and albumin products, solidifies its position as the largest subsegment in the market. Plasma-derived products such as clotting factors and immunoglobulin play a critical role in enhancing the quality of life for patients with chronic conditions, thus ensuring continued market growth. The increasing awareness of the importance of plasma donations and improvements in plasma fractionation technologies are further propelling the expansion of this segment.

End-User Segment Is Fastest Growing Due To Blood Banks' Expanding Role

Blood banks are rapidly emerging as the fastest-growing subsegment within the end-user category, largely driven by the rising demand for blood components in medical institutions globally. Blood banks are integral in ensuring the availability of blood supplies for emergency medical procedures, surgeries, and transfusions. As the number of accidents, surgeries, and cancer treatments increase, the demand for blood products within blood banks has grown exponentially.

The rise in voluntary blood donations, along with advancements in blood storage and processing technologies, has further supported the expansion of blood banks. These institutions are also benefiting from increased government funding and awareness campaigns to encourage blood donations. With the ability to store and supply blood components efficiently, blood banks are positioned at the forefront of ensuring global access to life-saving blood products.

Application Segment Is Largest Owing To High Demand for Transfusion

The transfusion application segment holds the largest share of the blood and blood components market, driven by its critical role in emergency medical care and surgeries. Blood transfusion is a vital procedure used to replace lost blood, typically in trauma, surgical operations, or severe anemia cases. With millions of transfusions performed annually worldwide, the demand for blood products continues to rise, particularly in hospitals, making transfusion the largest application segment.

Furthermore, technological advancements in blood typing, screening, and cross-matching have improved the safety and efficiency of transfusions, contributing to market expansion. The increased frequency of surgeries and trauma incidents in regions with aging populations further strengthens the demand for transfusion services, underscoring the significance of this application in the overall blood market.

Geography Segment Is Largest Owing To North America's Advanced Healthcare System

North America holds the largest share of the blood and blood components market, owing to the advanced healthcare infrastructure, robust blood donation systems, and a high prevalence of chronic diseases requiring blood transfusions. The United States, in particular, accounts for a substantial portion of the market, driven by an aging population, a high number of surgical procedures, and sophisticated medical research in blood-related therapies.

The region’s regulatory frameworks, which ensure the safety of blood products and promote voluntary blood donations, contribute significantly to market growth. Additionally, the presence of leading global players in the healthcare and blood components sector further strengthens North America's dominance, making it the largest region in the market.

Competitive Landscape of Blood and Blood Components Market

The global blood and blood components market is highly competitive, with a mix of well-established players and emerging companies. Leading companies such as Grifols, CSL Behring, Takeda Pharmaceutical Company, and Octapharma dominate the market with their diverse portfolios of plasma-derived therapies and blood products. These companies are actively expanding their market presence through strategic acquisitions, product innovations, and regulatory approvals.

The competitive landscape is characterized by collaborations, mergers, and acquisitions, aimed at strengthening the supply chain, improving blood product quality, and expanding into emerging markets. Research and development are also crucial for companies looking to differentiate themselves in the market, particularly in areas like plasma fractionation technologies and blood preservation solutions. The growing demand for blood-related treatments and therapies ensures that companies must remain agile in responding to market dynamics while maintaining high standards of safety and efficacy in their products.

List of Leading Companies:

• Grifols
• CSL Behring
• Takeda Pharmaceutical Company Limited
• Octapharma
• Fresenius Kabi AG
• Biotest AG
• Kedrion Biopharma
• Abbott Laboratories
• Sanquin Blood Supply Foundation
• BPL (British Pharmaceutical Industry)
• Héma-Québec
• Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
• Roche Diagnostics
• Baxalta (Shire)
• SinoPharm

Recent Developments:

• Grifols recently announced the launch of a new immunoglobulin product aimed at treating primary immune deficiencies.
• CSL Behring completed the acquisition of KEDPLASMA, expanding its network of blood collection centers.
• Takeda Pharmaceutical Company received regulatory approval for its new blood coagulation therapy aimed at hemophilia patients in Europe.
• Octapharma launched a new plasma-derived therapeutic product for the treatment of bleeding disorders.
• Fresenius Kabi has invested in advanced plasma fractionation technologies to increase production capacity for critical blood components.

Report Scope: